Interleukin-12 electroporation may sensitize 'cold' melanomas to immunotherapies

(American Association for Cancer Research) Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news